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Evaluation of Direct and Calcium-Mediated Short-Term Effects on Serum
Parathyroid Hormone Concentration
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Section of Nephrology and Research Laboratory for Calcium Metabolism, Departments of Internal Medicine and Orthopedic
Surgery, University of Zurich, Switzerland
Abstract. Eleven patients on chronic haemodialysis treat-
ment thrice weekly received 1 |ig 1,25(OH)2D3 i.v. after
each dialysis for 3 weeks. Phosphate binders were mainly
CaCO3, supplemented in a few patients by moderate
amounts of A1(OH)3. Ionised calcium was measured
by ion-selective electrode, normal values being 1.28—
1.42mmol/l. PTH was estimated by an N-terminal-
sensitive assay; normal values are <0.25ng/ml. Results
before and after 1,25(OH)2D3 were: ionised calcium
before haemodialysis, 1.19±0.12and 1.17±0.14; ionised
calcium after haemodialysis, 1.33 + 0.07 and 1.30 ±0.09;
PTH before haemodialysis, 1.39 ±0.71 and 1.38 ±0.69;
PTH after haemodialysis, 0.64 ±0.22 and 0.60 ±0.17;
Phosphate before haemodialysis, 1.85 + 0.48 and 2.18 +
0.43 (/><0.05). No change of PTH concentration and
ionised calcium before and after haemodialysis treatment
could be documented after i.v. 1,25(OH)2D3 treatment.
Mild and severe hyperparathyroidism were indistinguish-
able. Increased serum calcium concentrations therefore
appear to be required for the suppression of PTH
secretion by i.v. 1,25(OH)2D3 therapy.
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Introduction
Excessive parathyroid hormone (PTH) secretion is an
important cause of renal osteodystrophy [1]. Serum PTH
concentrations are increased early in the course of renal
disease and are linked initially to predominantly intra-
cellular phosphate retention [2]. This is followed at later
stages of the disease by an extracellular increase of
inorganic phosphate [3]. Phosphate retention is related to
reduced ionised calcium concentrations, suppressed syn-
thesis of 1,25(OH)2 vitamin D3 (1,25(OH)2D3) and the
expression of its receptors. All these factors participate in
the aetiology of renal hyperparathyroidism [4].
Suppression of parathyroid hormone secretion in renal
disease is related to elevated serum ionised calcium con-
centrations [5]. Normal serum PTH values, however, are
difficult to reach and are usually only observed in hyper-
calcaemic patients [6]. This was true with calcium
supplementation as well as with the peroral adminis-
tration of vitamin D metabolites [7]. A new approach for
the treatment of renal hyperparathyroidism was initiated
by the group of Slatopolsky with the use of intravenously
administered 1,25(OH)2D3 [8]. The authors postulated
that a more pronounced suppression of parathyroid
hormone secretion was brought about with intravenous
1,25(OH)2D3 than with its peroral administration [9].
The present study was carried out to differentiate
between effects of intravenous 1,25(OH)2D3 and the
increase in serum ionised calcium before and during
haemodialysis treatment. Low doses of intravenously
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administrated 1,25(OH)2D3 did not change serum
calcium values at the start of haemodialysis; treatment-
related augmentation of ionised calcium suppressed PTH
to the same extent before and after i.v. 1,25(OH)2D3.
Patients and Methods
The study was carried out in 11 patients on chronic
haemodialysis, mean age 36.2+ 14.2 (SD) years, treated
thrice weekly for 2.5-3.5 h by means of high-flux polysul-
phone filters (Fresenius F60), using acetate dialysate
with 1.5 mmol/1 of calcium (Table 1). One microgram of
1,25(OH)2D3 (Abbott Company) was administered i.v.
after each dialysis session for 3 weeks. Serum ionised
calcium by ion-selective electrode (AVL company,
CV = 0.7%), immunoreactive N-terminal parathyroid
hormone (PTH) (CV=14%) [10] and inorganic phos-
phorus (ammonium molybdate reaction, CV=1.8%)
were measured before and after i.v. 1,25(OH)2D3 treat-
ment. Moreover, effects of individual haemodialysis treat-
ments on the increase of the serum ionised calcium and the
suppression of PTH were evaluated. All the patients were
kept on calcium carbonate as a phosphate-binding agent,
supplemented in some candidates with small doses of
aluminium hydroxide. Mean serum aluminium values
were increased 5-fold as compared to normal subjects,
but distributed within the Gaussian distribution of
the haemodialysis population. Statistical analysis was
performed by Student's t-test for paired data.
Results (Fig. 1)
Before treatment with 1,25(OH)2D3, the serum ionised
calcium values amounted to 1.19 + 0.12 mmol/1 (normal
1.28-1.42 mmol/1, mean ±2 SD). During individual
haemodialysis treatments, serum ionised calcium was
increased to 1.33 + 0.7 mmol/1. Corresponding values,
after 3 weeks of i.v. 1,25(OH)2D3 treatment were
1.17 ±0.14 mmol/1 and 1.30 + 0.09 mmol/1 respectively.
N-terminal PTH concentrations were 1.39 + 0.71 ng/ml
and 0.64 + 0.22 ng/ml before and after dialysis prior to
1,25(OH)2D3 treatment (normal < 0.25 ng/ml). After
3 weeks i.v. 1,25(OH)2D3 PTH amounted to 1.38 ±
0.69 ng/ml before and 0.60+ 0.17 ng/ml after haemo-
dialysis. Serum phosphorus concentrations amounted
to 1.85 ±0.48 mmol/1 (normal 0.7-1.6 mmol/1) before
1,25(OH)2D3 treatment. After 1,25(OH)2D3 the values
were slightly increased to 2.18±0.43 mmol/1 (P<0.05).
On correlation analysis the decrease of PTH was related
to the increase of serum ionised calcium during haemo-
dialysis before as well as after 1,25(OH)2D3 treatment
(Fig. 2).
Discussion
Increased serum ionised calcium concentrations are
known to suppress PTH secretion [1]. In chronic renal
insufficiency with and without dialysis treatment, near
normal PTH values have only been observed during
hypercalcaemia. This observation was related by Brown
and others to an increased set point for PTH secretion in
hyperplastic parathyroid glands [11-13]. Besides calcium
supplementation, peroral vitamin D and its metabolites
reduced serum PTH in concert with increased calcium
values. Reduced serum PTH values were anticipated from
in-vitro results, revealing suppression of mRNA values
encoding for pre-pro-PTH by 1,25(OH)2D3 independent
of ambient calcium concentrations [11,12]. Several other
groups showed suppression of PTH by 1,25(OH)2D3 in
vitro [14-16].
In contrast, direct suppression of the PTH secretion by
1,25(OH)2D3 is questionable in vivo and has not been
universally demonstrated [7]. With peroral vitamin D
metabolites a direct suppression of PTH secretion could
not be dissociated from concomitantly increased serum
calcium concentrations. An alternative arose when
1,25(OH)2D3 administered intravenously was claimed to
suppress PTH secretion directly [8]. The mechanism was
thought to be increased sensitivity to calcium-induced
suppression of PTH secretion [9]. In these studies calcium
was increased within minutes of i.v. 1,25(OH)2D3 admin-
istration and almost simultaneously, PTH decreased.
The two variables, increased serum concentrations of
1,25(OH)2D3 and calcium, have not been clearly separ-
ated. None the less, increased serum calcium values in
concert with or due to i.v. 1,25(OH)2D3 are effective in
reducing serum PTH.
With the present study a potential direct suppression of
PTH secretion by i.v. 1,25(OH)2D3 in the absence of
increased ionised calcium concentration was investigated.
Moreover, reduction of serum PTH levels as a conse-
quence of haemodialysis treatment increasing serum
calcium concentrations was confirmed [9]. Serum ionised
calcium concentrations before the start of haemodialysis
were stable and in a slightly hypocalaemic range; 1 ug
1,25(OH)2D3 administered three times weekly by the i.v.
route for 3 weeks did not alter mean serum PTH values in
our patients. Moreover, grouping of the patients with
great and small initial PTH values did not affect our con-
clusions. The quantity of phosphate binders administered
was left unchanged. As a result of the treatment with
1,25(OH)2D3 serum inorganic phosphorus values were
slightly elevated (/><0.05). This observation reveals a
,25(OH)2D3 i.v. and Serum Parathyroid Hormone 459
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Fig. 1. Serum ionised calcium, PTH and phosphorus before and after i.v.
1,25(OH)2D3. Effects of haemodialysis treatment.
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Fig. 2. Correlation between changes in ionised serum calcium and PTH
during haemodialysis treatment before and after 1,25(OH)2D3.
biological effect of the 1,25(OH)2D3 administered and
perhaps can be considered as a contribution to the lack of
suppressive effect of i.v. administered 1,25(OH)2D3 on
PTH, as recently suggested by Slatopolsky et al [17]. In
contrast to this opinion Brandi et al [18] showed a sup-
pression of PTH with i.v. 1-a-hydroxyvitamin D3 despite
a marked increase of serum phosphorus; the suppression
of PTH, however, was accompanied by a marked increase
in the serum calcium concentration.
The 1,25(OH)2D3 dose used was taken from published
data which showed suppression of PTH in some patients
[8]. This was accentuated during prolonged treatment
with increasing doses of 1,25(OH)2D3 concomitant with
an increase of the serum ionised calcium concentrations.
More prolonged treatment with 1 ug of 1,25(OH)2D3 as
used in the present study might suppress PTH secretion in
the absence of increased serum calcium concentrations.
Serum ionised calcium was always elevated during
haemodialysis treatment, and PTH reduced accordingly.
Here also, the values were indistinguishable before and
after 1,25(OH)2D3 treatment. With a larger dose of
1,25(OH)2D3 during a prolonged treatment time and
while decreasing the dialysate calcium to 2.5mEq/l,
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Dunlay et al [19] showed an effect on PTH without
a significant increase in serum calcium concen-
tration. The sigmoidal shape relation between PTH and
haemodialysis-induced hypo- and hypercalcaemia was
displaced, showing a smaller PTH stimulation at low
serum calcium concentrations after 1,25(OH)2D3; pre-
and post-treatment relations, however, were only margi-
nally affected. With a long-term intermittent treatment by
i.v. calcitriol inducing an increase of the serum calcium
concentration, an amelioration of osteitis fibrosa in
dialysis patients was recently demonstrated by bone
histomorphometry [20].
In conclusion, short-term i.v. administration of
1,25(OH)2D3 in slightly hypocalcaemic haemodialysis
patients did not reduce serum PTH concentrations.
Suppression of serum PTH by haemodialysis-induced
increases of the ionised serum calcium concentrations was
the same before and after i.v. 1,25(OH)2D3 treatment.
These data might suggest a synergistic effect of
1,25(OH)2D3 and the increase in serum ionised
calcium concentration for the suppression of serum PTH
concentrations in haemodialysis patients.
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